Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D₃ analogue, in a phase I study of patients with advanced malignancies

By Wieder Robert   Novick Steven C.   Hollis Bruce W.   Bryan Margarette   Chanel Suzanne M.   Owusu Kate   Camastra Danielle   Saunders Tracie   Pliner Lillian   Harrison Jonathan   Bonate Peter   Williams Tom   Soignet Steven  

Investigational New Drugs, Vol. 21, Iss. 4, 2003-11 ,pp. : 445-452

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

By Ganesan Prasanth   Piha-Paul Sarina   Naing Aung   Falchook Gerald   Wheler Jennifer   Janku Filip   Zinner Ralph   Laday Shell   Kies Merrill   Tsimberidou Apostolia  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1505-1513

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

By Ganesan Prasanth   Piha-Paul Sarina   Naing Aung   Falchook Gerald   Wheler Jennifer   Fu Siqing   Hong David   Kurzrock Razelle   Janku Filip   Laday Shell   Bedikian Agop   Kies Merrill   Wolff Robert   Tsimberidou Apostolia  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 279-286

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors

By  

Current Clinical Pharmacology, Vol. 8, Iss. 1, 2013-02 ,pp. : 81-88

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite